# Everest Medicines and Hainan Herui have entered into a commercialization collaboration relating to Hainan Herui's budesonide enteric capsules

- Link: https://www.thailand-business-news.com/pr-news/everest-medicines-and-hainan-herui-have-entered-into-a-commercialization-collaboration-relating-to-hainan-heruis-budesonide-enteric-capsules
- Published: 2026-06-24T14:07:00+07:00
- Author: PR Newswire

SHANGHAI, June 24, 2026 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, "Everest",
or the "Company"), a biopharmaceutical company focused on the discovery, clinical
development, manufacturing, and commercialization of innovative therapeutics, today
announced that Everest Medicines and Hainan Herui have entered into a commercialization
collaboration relating to Hainan Herui’s budesonide enteric capsules, which were
approved by the National Medical Products Administration (NMPA) in December 2025.

Pursuant to this collaboration, Hainan Herui’s budesonide enteric capsules will 
be permitted to be launched in the Chinese mainland market, with Everest Medicines
responsible for their commercialization. Everest Medicines will provide rigorous
technical guidance and quality audits over Hainan Herui’s manufacturing and supply
processes. This collaboration is expected to enhance patient access to the combined
franchise of NEFECON^(®) and Hainan Herui’s budesonide enteric capsules. This collaboration
is subject to the satisfaction of customary closing conditions.

**About NEFECON^(®)**

NEFECON^(®) is an oral, delayed release formulation of budesonide, a corticosteroid
with potent glucocorticoid activity and weak mineralocorticoid activity that undergoes
substantial first pass metabolism. NEFECON^(®) was designed as a 4 mg delayed release
capsule and is enteric coated so that it would remain intact until it reaches the
ileum. Each capsule contains coated beads of budesonide that target mucosal B-cells
present in the ileum, including the Peyer’s patches, which are responsible for the
production of galactose-deficient IgA1 antibodies (Gd-IgA1) causing IgA nephropathy.

NEFECON^(®) was approved in November 2023 through National Medical Products Administration(
NMPA)’s priority review for the treatment of primary IgA nephropathy in adults at
risk of disease progression. It was subsequently included in the National Reimbursement
Drug List in November 2024, and received full approval from the NMPA in April 2025,
irrespective of proteinuria levels, benefiting most individuals living with IgA 
nephropathy.

It has been approved across all Everest Medicines’ territories, including mainland
China, Hong Kong SAR, Macau SAR, Taiwan region, China, as well as Singapore and 
South Korea.

**About Everest Medicines**

Everest Medicines is a biopharmaceutical company focused on discovering, developing,
manufacturing and commercializing innovative pharmaceutical products that address
critical unmet medical needs for patients in global markets. The management team
of Everest Medicines has deep expertise and an extensive track record both in China
and with leading global pharmaceutical companies.

The Company’s therapeutic areas of focus include CKM (cardiovascular, kidney, and
metabolic), autoimmune, ophthalmology and critical care. Everest Medicines has developed
a fully integrated commercialization platform that combines omnichannel commercial
capabilities with end-to-end product lifecycle management. Leveraging its proprietary
mRNA platform, the Company is advancing its existing pipeline, including mRNA in
vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional
high-value therapeutic areas with blockbuster potential, and accelerating its global
expansion. For more information, please visit the Company’s website: [www.everestmedicines.com](http://www.everestmedicines.com/).

**Forward-Looking Statements**

This news release may make statements that constitute forward-looking statements,
including descriptions regarding the intent, belief or current expectations of the
Company or its officers with respect to the business operations and financial condition
of the Company, which can be identified by terminology such as "will," "expects,""
anticipates," "future," "intends," "plans," "believes," "estimates," "confident"
and similar statements. Such forward-looking statements are not guarantees of future
performance and involve risks and uncertainties, or other factors, some of which
are beyond the control of the Company and are unforeseeable. Therefore, the actual
results may differ from those in the forward-looking statements as a result of various
factors and assumptions, such as future changes and developments in our business,
competitive environment, political, economic, legal and social conditions. The Company
or any of its affiliates, directors, officers, advisors or representatives has no
obligation and does not undertake to revise forward-looking statements to reflect
new information, future events or circumstances after the date of this news release,
except as required by law.

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Everest Medicines and Hainan Herui have entered into a commercialization collaboration relating to Hainan Herui's budesonide enteric capsules ](http://www.prnasia.com/story/archive/4991086_AE91086_0?rand=184833)
